Translating basic mechanisms of IgG effector activity into next generation cancer therapies
about
Immunoregulatory functions of immune complexes in vaccine and therapyDirect Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future TherapiesHuman IgG4: a structural perspectiveEngineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131Glycan analysis of therapeutic glycoproteinsAntibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer.Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes.Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activityConformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesA comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.The use of lectin microarray for assessing glycosylation of therapeutic proteins.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.Highly parallel characterization of IgG Fc binding interactions.Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.IgG Glycome in Colorectal Cancer.Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.
P2860
Q26738396-77037613-0883-485C-B251-96D88454CDB5Q26752558-042356D3-855E-464A-91AE-292FCEE51104Q26779758-DAE177D7-EB8C-4D3A-BEAF-D63B0416B2ECQ27678516-31E31E34-E971-410A-A5A3-2AF4829E24AFQ28082842-2E7D3A8D-C76C-4F9C-B1A0-F91B20D48AB5Q30276243-E98764D8-A57A-4CFF-AAB9-60AFFACD9936Q33759526-AFD68CDF-A7C1-40CD-845D-C7D9C1DD9FBFQ33891585-6F425002-8014-46F4-9DEC-6FD0B5BA8D5DQ34204325-B5F3CF17-43AA-4F32-A647-C21254D53C62Q34978570-1965A9A9-9ECE-4A18-B15B-A58B1E8FD4A5Q37125759-F7B05FB0-2D86-47B1-B566-155CBA1920A5Q37138274-F3C3778D-BCAB-4E2C-A078-D622FD3BAC1EQ37138938-2C6F622A-58C1-41C8-858D-31F642B63E81Q38364462-D8FD14AB-3D0F-4B35-BF4D-90FB6BA84962Q38717198-0ED0E190-CBE1-47BD-8F3F-F7E9620B17C5Q38718049-B00716B6-A238-4864-B2F7-B2B2FC7DA03FQ38730371-29C5494E-4CDE-4600-BFAB-5C0B8240B25EQ42107564-F078BA3D-B5D2-473C-81B2-263F1F07DEB2Q42171615-E6D77DD2-E2A5-479D-85AB-542036505060Q42909129-E99F17FA-80F0-40C2-A622-384A16D12441Q48825054-F009BAC8-97A5-4BAE-8BF1-3B441B389942Q50856757-54F11E14-FA2B-4756-9263-25FCAEAD80BDQ52770201-31FF1A15-2210-4974-A643-B586EB22FFA9Q53078816-DF5643DF-AC8B-4082-896F-358CB462277AQ55359818-B6F88714-D497-49D9-8A1B-10826552B44D
P2860
Translating basic mechanisms of IgG effector activity into next generation cancer therapies
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Translating basic mechanisms o ...... xt generation cancer therapies
@ast
Translating basic mechanisms o ...... xt generation cancer therapies
@en
Translating basic mechanisms o ...... xt generation cancer therapies
@nl
type
label
Translating basic mechanisms o ...... xt generation cancer therapies
@ast
Translating basic mechanisms o ...... xt generation cancer therapies
@en
Translating basic mechanisms o ...... xt generation cancer therapies
@nl
prefLabel
Translating basic mechanisms o ...... xt generation cancer therapies
@ast
Translating basic mechanisms o ...... xt generation cancer therapies
@en
Translating basic mechanisms o ...... xt generation cancer therapies
@nl
P2860
P3181
P1433
P1476
Translating basic mechanisms o ...... xt generation cancer therapies
@en
P2093
Nimmerjahn F
Ravetch JV
P2860
P3181
P407
P577
2012-01-01T00:00:00Z